Line 56: | Line 56: | ||
<li><a href="https://2018.igem.org/Team:UST_Beijing/Model">Model</a ></li> | <li><a href="https://2018.igem.org/Team:UST_Beijing/Model">Model</a ></li> | ||
<li><a href="https://2018.igem.org/Team:UST_Beijing/Parts">Parts</a ></li> | <li><a href="https://2018.igem.org/Team:UST_Beijing/Parts">Parts</a ></li> | ||
− | <li><a href="https://2018.igem.org/ | + | <li><a href="https://2018.igem.org/Team:UST_Beijing/Safety">Safety</a ></li> |
<li class="dropdown"><a href="javascript:{}">Awards</a > | <li class="dropdown"><a href="javascript:{}">Awards</a > | ||
<ul class="dropdown-menu"> | <ul class="dropdown-menu"> |
Revision as of 15:11, 12 October 2018
Ginseng products offer a unique opportunity to meet the atherosclerosis challenge. Herbs containing ginsenosides include: Ginseng, Western Ginseng, Notoginseng, Jiaogulan etc. Current herb preparation and administration practice results in poor absorption profile limit its efficacy and cost-effectiveness. Since the ginseno-sterols are responsible for their main pharmacological effects, how to achieve effective concentration of sterol in the human body becomes critical.
In the past, two approaches have been tried to achieve this: (1) Synthesize ginseno-sterols in situ. Pro: no need to plant ginseng and harvest, continuous supply of ginseno-sterols; Con: interference with host physiology, lack of control in production. (2) Produce beta-glucosides in the gut micro-organism. Pro: convenient to hydrolyze ginsenosides in the gut; Con: interference with host gut physiology and probiotics.
In the current third approach, we use chemical reaction to hydrolyze the conjugated sugars, to satisfy “No-release” policy if iGEM safety requirement.
A synthetic beta-glucosidase gene is introduced into E.coli, along with PNPG as illustrated below. The enzyme (3D structure is displayed on the left) will make a yellow color product in the medium, which is measured by spectrometry